Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the Code of Practice has come to an end. The company’s return to full membership of the ABPI follows extensive audits of Novo Nordisk’s compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA). Richard […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!